$281 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 30 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 69.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $59,503,000 | +112.5% | 2,426,701 | -17.6% | 21.16% | +58.9% |
| XBI | New | SPDR SERIES TRUSTput | $17,542,000 | – | 200,000 | +100.0% | 6.24% | – |
| KDMN | Sell | KADMON HLDGS INC | $15,692,000 | -22.1% | 7,617,500 | -0.2% | 5.58% | -41.8% |
| ADVM | Buy | ADVERUM BIOTECHNOLOGIES INC | $14,149,000 | +193.8% | 1,190,000 | +29.5% | 5.03% | +119.7% |
| VCYT | Buy | VERACYTE INC | $13,728,000 | +43.8% | 481,500 | +26.2% | 4.88% | +7.5% |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $12,680,000 | +312.5% | 478,500 | +185.7% | 4.51% | +208.4% |
| ARVN | Buy | ARVINAS INC | $12,116,000 | +161.4% | 551,000 | +75.5% | 4.31% | +95.5% |
| ARGX | Buy | ARGENX SEsponsored adr | $11,468,000 | +44.7% | 81,000 | +27.6% | 4.08% | +8.2% |
| AXSM | New | AXSOME THERAPEUTICS INC | $11,266,000 | – | 437,500 | +100.0% | 4.01% | – |
| BHVN | Buy | BIOHAVEN PHARMACTL HLDG CO L | $11,166,000 | +5.3% | 255,000 | +23.8% | 3.97% | -21.3% |
| INSM | Buy | INSMED INC | $11,149,000 | +3.7% | 435,500 | +17.7% | 3.96% | -22.5% |
| MIST | New | MILESTONE PHARMACEUTICALS IN | $9,421,000 | – | 347,000 | +100.0% | 3.35% | – |
| ATNX | New | ATHENEX INC | $9,356,000 | – | 472,500 | +100.0% | 3.33% | – |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $8,132,000 | +91.7% | 671,500 | +99.0% | 2.89% | +43.4% |
| VRAY | Buy | VIEWRAY INC | $7,422,000 | +23.2% | 842,500 | +3.4% | 2.64% | -7.9% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $6,917,000 | +23.2% | 701,500 | +27.0% | 2.46% | -7.8% |
| MRTX | Buy | MIRATI THERAPEUTICS INC | $6,438,000 | +114.2% | 62,500 | +52.4% | 2.29% | +60.2% |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $6,152,000 | – | 935,000 | +100.0% | 2.19% | – |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $6,056,000 | +25.7% | 384,500 | +16.9% | 2.15% | -6.0% |
| IRIX | Sell | IRIDEX CORP | $5,329,000 | -0.5% | 1,171,300 | -0.3% | 1.90% | -25.6% |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $4,718,000 | -19.8% | 213,000 | +3.6% | 1.68% | -40.0% |
| FOLD | New | AMICUS THERAPEUTICS INC | $4,368,000 | – | 350,000 | +100.0% | 1.55% | – |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $3,721,000 | – | 79,000 | +100.0% | 1.32% | – |
| IMMU | Sell | IMMUNOMEDICS INC | $3,121,000 | -67.5% | 225,000 | -55.0% | 1.11% | -75.7% |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO Lput | $2,190,000 | – | 50,000 | +100.0% | 0.78% | – |
| BHVN | BIOHAVEN PHARMACTL HLDG CO Lcall | $2,190,000 | -14.9% | 50,000 | 0.0% | 0.78% | -36.4% | |
| ASMB | Sell | ASSEMBLY BIOSCIENCES INC | $2,131,000 | -85.8% | 158,000 | -79.2% | 0.76% | -89.4% |
| DHR | New | DANAHER CORPORATION | $1,644,000 | – | 11,500 | +100.0% | 0.58% | – |
| CMRX | New | CHIMERIX INC | $1,210,000 | – | 280,000 | +100.0% | 0.43% | – |
| CEMI | CHEMBIO DIAGNOSTICS INC | $254,000 | +10.0% | 41,667 | 0.0% | 0.09% | -18.2% | |
| NVAX | Exit | NOVAVAX INCput | $0 | – | -250,000 | -100.0% | -0.07% | – |
| BCRX | Exit | BIOCRYST PHARMACEUTICALS | $0 | – | -25,000 | -100.0% | -0.10% | – |
| STRO | Exit | SUTRO BIOPHARMA INC | $0 | – | -45,500 | -100.0% | -0.25% | – |
| ALLK | Exit | ALLAKOS INC | $0 | – | -13,500 | -100.0% | -0.26% | – |
| GOSS | Exit | GOSSAMER BIO INC | $0 | – | -60,000 | -100.0% | -0.62% | – |
| AMRN | Exit | AMARIN CORP PLCspons adr new | $0 | – | -87,500 | -100.0% | -0.86% | – |
| QTNT | Exit | QUOTIENT LTD | $0 | – | -280,000 | -100.0% | -1.20% | – |
| ACER | Exit | ACER THERAPEUTICS INC | $0 | – | -147,000 | -100.0% | -1.70% | – |
| ALEC | Exit | ALECTOR INC | $0 | – | -200,000 | -100.0% | -1.78% | – |
| ENTA | Exit | ENANTA PHARMACEUTICALS INC | $0 | – | -61,000 | -100.0% | -2.77% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -517,500 | -100.0% | -3.27% | – |
| DERM | Exit | DERMIRA INC | $0 | – | -636,500 | -100.0% | -4.10% | – |
| CASM | Exit | CAS MED SYS INC | $0 | – | -5,263,508 | -100.0% | -6.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.